Fabio Piscaglia, Francesco Tovoli, Patrizia Pini, Veronica Salvatore – 13 September 2017

Maurizio Cesari, Anna Chiara Frigo, Marta Tonon, Paolo Angeli – 13 September 2017 – Cirrhotic cardiomyopathy is associated with poor outcomes in patients with cirrhosis. We investigated if subclinical cardiac morphologic and functional modifications can influence survival in patients with cirrhosis during follow‐up. A series of patients with cirrhosis without cardiovascular or pulmonary disease underwent standard and tissue Doppler echocardiography to assess left ventricular geometry, systolic/diastolic function, and the main haemodynamic parameters.

Graham F. Brady, Raymond Kwan, Peter J. Ulintz, Phirum Nguyen, Shirin Bassirian, Venkatesha Basrur, Alexey I. Nesvizhskii, Rohit Loomba, M. Bishr Omary – 13 September 2017 – Nonalcoholic fatty liver disease (NAFLD) is becoming the major chronic liver disease in many countries. Its pathogenesis is multifactorial, but twin and familial studies indicate significant heritability, which is not fully explained by currently known genetic susceptibility loci. Notably, mutations in genes encoding nuclear lamina proteins, including lamins, cause lipodystrophy syndromes that include NAFLD.

Adam C. Winters, Douglas Tremblay, Suzanne Arinsburg, John Mascarenhas, Thomas D. Schiano – 13 September 2017 – Hereditary hemochromatosis (HH) is a genetic disorder of iron metabolism that may lead to iron overload. Clinical penetrance is low, however those afflicted may develop cirrhosis, hepatocellular carcinoma, diabetes mellitus, and cardiomyopathy. Treatment of HH involves regular phlebotomy to reduce the systemic iron burden.

This webinar, presented by the Cholestatic and Biliary Diseases SIG, will focus on the complex topic of Surrogate Endpoints in PSC. The webinar will discuss the Natural History of PSC and the resulting difficulty in identifying relevant endpoints for prognostication and for use in clinical trials. Promising candidate endpoints will be specifically addressed based on the latest clinical research.David Assis (Moderator) Dr. David Assis is an assistant professor of medicine in the section of Digestive Diseases at Yale University School of Medicine.

Jordi Rimola, Álvaro Díaz‐González, Anna Darnell, María Varela, Fernando Pons, Manuel Hernandez‐Guerra, Manuel Delgado, Javier Castroagudin, Ana Matilla, Bruno Sangro, Carlos Rodriguez de Lope, Margarita Sala, Carmen Gonzalez, Carlos Huertas, Beatriz Minguez, Carmen Ayuso, Jordi Bruix, María Reig – 12 September 2017 – The clinical benefit of sorafenib in patients with hepatocellular carcinoma (HCC) has been undervalued due to the absence of complete responses, even though patients who develop early dermatologic reactions have shown to have a positive outcome.

Mutaz Sultan, Anuradha Rao, Orly Elpeleg, Frédéric M. Vaz, Bassam Abu‐Libdeh, Saul J. Karpen, Paul A. Dawson – 12 September 2017 – Primary bile acid malabsorption is associated with congenital diarrhea, steatorrhea, and a block in the intestinal return of bile acids in the enterohepatic circulation. Mutations in the ileal apical sodium‐dependent bile acid transporter (ASBT; SLC10A2) can cause primary bile acid malabsorption but do not appear to account for most familial cases.

Bibo Wang, Jing Fu, Ting Yu, An Xu, Wenhao Qin, Zhishi Yang, Yao Chen, Hongyang Wang – 12 September 2017 – Conflicting effects of antioxidant supplementation on cancer prevention or promotion is of great concern to healthy people and cancer patients. Despite recent studies about antioxidants accelerating the progression of lung cancer and melanoma, antioxidants may still play a role in cancer prevention. Both tumor and antioxidants types influence the actual efficacy.

For most of the modern era in medicine, cirrhosis has been regarded as an irreversible condition. For most of the modern era in medicine, cirrhosis has been regarded as an irreversible condition.  Contrary to this perception, cirrhosis in animal models of liver injury has long been known to be reversible and case reports from decades ago documenting “reversal” of cirrhosis indicated that fibrosis regression was also possible in human liver disease.

Rohit Loomba, Eric Lawitz, Parvez S. Mantry, Saumya Jayakumar, Stephen H. Caldwell, Hays Arnold, Anna Mae Diehl, C. Stephen Djedjos, Ling Han, Robert P. Myers, G. Mani Subramanian, John G. McHutchison, Zachary D. Goodman, Nezam H. Afdhal, Michael R. Charlton, for the GS‐US‐384‐1497 Investigators – 11 September 2017 – Inhibition of apoptosis signal–regulating kinase 1, a serine/threonine kinase, leads to improvement in inflammation and fibrosis in animal models of nonalcoholic steatohepatitis.